ANI Pharmaceuticals, Inc
ANI Pharmaceuticals is a U.S.-based biopharmaceutical company that develops, manufactures, and commercializes prescription therapeutics across Rare Disease, Generics, and Brands. Its portfolio includes specialty products such as Cortrophin Gel, ILUVIEN, and YUTIQ, alongside a broader generics business supported by its own manufacturing footprint in Minnesota and New Jersey.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes Cortrophin Gel, ILUVIEN, YUTIQ, and other branded specialty products sold through limited-distribution channels.
Includes generic prescription pharmaceuticals sold primarily through wholesalers, retailers, and group purchasing organizations.
Includes royalty income and other service revenue tied to pharmaceutical commercialization and partnerships.
Products
Reported · share of revenue- Sales of Generic Pharmaceutical Products43.5 %
- Sales of Cortrophin Gel39.4 %
- Sales of ILUVIEN and YUTIQ8.5 %
- Sales of Established Brands6.9 %
- Sales of Royalties and Other Pharmaceutical Services1.7 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
ANI sells mainly to pharmaceutical distribution intermediaries, specialty pharmacies, retail chains, and healthcare providers rather than directly to end patients. Its rare disease products depend on a narrower set of specialty pharmacies, hospitals, clinics, and physicians, while generics are sold through highly consolidated wholesaler and retail channels. Customer concentration is meaningful, with a small number of large customers representing a substantial share of revenue.
Buy generic and branded products in bulk for downstream distribution; important because ANI relies on a concentrated U.S. channel structure.
Dispense rare disease products such as Cortrophin Gel to eligible patients and support limited-distribution commercialization.
Purchase generic and branded medicines for broad consumer access through national pharmacy networks.
Buy and administer ILUVIEN and other specialty products in clinical settings, especially in ophthalmology.
Influence formulary access, rebates, and pricing terms that affect realized revenue and market penetration.
Strategy
ANI's strategy centers on expanding its rare disease and specialty franchise while maintaining a cash-generative generics base. The Alimera acquisition broadened its ophthalmology portfolio and international footprint, and the company continues to invest in commercialization, manufacturing capability, and selective acquisitions to deepen its product pipeline.
Higher-value specialty products can improve growth and diversify away from commoditized generics pricing.
The acquisition adds products, international channels, and a stronger specialty platform.
Owning manufacturing capacity supports product launches and reduces dependence on third parties.
ANI seeks additional products and assets to diversify revenue and support growth.
Geography
2025ANI is headquartered and primarily operates in the United States, where most of its manufacturing, commercialization, and customer relationships are concentrated. The company also has international exposure through ILUVIEN, including direct marketing operations in Germany, the United Kingdom, Portugal, and Ireland, plus partnerships in Europe, Asia, and the Middle East. Geography matters because rare disease and ophthalmology products have broader non-U.S. reach than the generics business, while manufacturing and regulatory compliance remain anchored in the U.S.
Share of the revenue the company reports by geography.
Risks
ANI faces concentration risk from a small number of large customers and channel partners, which can pressure pricing and volumes if relationships change. Its specialty products also depend on reimbursement, regulatory approvals, and successful commercialization, while generics remain exposed to intense price competition and supply-chain fragility. Debt, covenant compliance, and third-party manufacturing dependence add financial and operational risk.
- Generic pricing pressureImpact: HighLikelihood: High
Generics compete mainly on price, contract terms, and service levels, which can compress margins and reduce volumes.
- Customer concentrationImpact: HighLikelihood: Medium
A small number of wholesalers and distributors account for a large share of revenue, so lost business or renegotiated terms would materially affect sales.
Exposure: Three customers represented about 53% of 2025 net revenue
- Commercialization risk for Cortrophin Gel and ILUVIENImpact: HighLikelihood: Medium
Specialty products must gain and sustain market acceptance to offset generics volatility.
- Supply chain and single-source manufacturing dependenceImpact: HighLikelihood: Medium
Limited API suppliers and third-party manufacturers can cause delays, shortages, or compliance issues.
- Regulatory and healthcare law complianceImpact: HighLikelihood: Medium
Pharmaceutical operations are exposed to FDA, reimbursement, anti-kickback, and foreign regulatory regimes.
- Debt and covenant complianceImpact: MediumLikelihood: Medium
Indebtedness and restrictive covenants can limit cash flow flexibility and trigger acceleration if breached.
Accounting
Judgemental itemsChargebacks, rebates, returns, and discounts are estimated in the period of sale and can materially change net revenue.
Impact: Affects reported net sales and gross margin
Product revenue is recognized at transfer of control, so channel timing and customer terms matter.
Impact: Can shift revenue between quarters
The Alimera acquisition adds acquired intangibles and goodwill that must be tested for impairment.
Impact: Potential non-cash impairment charges
The Oakville site sale and prior restructuring actions create gains, charges, and comparability issues.
Impact: Can distort year-over-year operating trends
Manufacturing complexity and product mix can affect inventory valuation and obsolescence assumptions.
Impact: Affects cost of goods sold and working capital
Similar listed companies
Publicly listed companies with a comparable business focus.
Zai Lab Ltd
ZLAB · Pharmaceutical Preparations
Zai Lab Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for oncology, immunology, neuroscience, and infectious diseases.
Anvi Global Holdings, Inc.
ANVI · Retail-Food Stores
EyePoint, Inc.
EYPT · Laboratory Analytical Instruments
Sanofi
SNY · Pharmaceutical Preparations
Sanofi is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines.
AN2 Therapeutics, Inc.
ANTX · Pharmaceutical Preparations
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Last updated: 24/09/2026